These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 11096349)

  • 1. Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview.
    Terakawa N
    Oncology; 2000; 59 Suppl 1():3-4. PubMed ID: 11096349
    [No Abstract]   [Full Text] [Related]  

  • 2. Playing the old piano: another tune for endocrine therapy?
    Hayes DF
    J Natl Cancer Inst; 2003 Nov; 95(21):1565-7. PubMed ID: 14600082
    [No Abstract]   [Full Text] [Related]  

  • 3. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
    Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
    J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Playing the old piano: another tune for endocrine therapy.
    Koeberle D; Perey L; Thuerlimann B;
    J Natl Cancer Inst; 2004 Apr; 96(7):555-6; author reply 556-7. PubMed ID: 15069120
    [No Abstract]   [Full Text] [Related]  

  • 5. Tamoxifen prevention of breast cancer: an instance of the fingerpost.
    Lippman SM; Brown PH
    J Natl Cancer Inst; 1999 Nov; 91(21):1809-19. PubMed ID: 10547388
    [No Abstract]   [Full Text] [Related]  

  • 6. How is tamoxifen's action subverted?
    Jordan VC
    J Natl Cancer Inst; 2000 Jan; 92(2):92-4. PubMed ID: 10639501
    [No Abstract]   [Full Text] [Related]  

  • 7. Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma.
    Lamb CA; Helguero LA; Fabris V; Lucas C; Molinolo AA; Lanari C
    Breast Cancer Res Treat; 2003 May; 79(1):25-35. PubMed ID: 12779079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention of breast cancer.
    O'Regan RM; Jordan VC
    Cancer Treat Res; 2001; 106():137-54. PubMed ID: 11225001
    [No Abstract]   [Full Text] [Related]  

  • 9. Searching for an ideal SERM: Mining tamoxifen structure-activity relationships.
    Price S; Bender SG; Yahn R; Till NA; Varady S; LaLonde RL
    Bioorg Med Chem Lett; 2021 Nov; 52():128383. PubMed ID: 34592434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
    Pickar JH; Komm BS
    Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
    Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
    Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
    Obrero M; Yu DV; Shapiro DJ
    J Biol Chem; 2002 Nov; 277(47):45695-703. PubMed ID: 12244117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
    Reiter R; Oh AS; Wellstein A; Riegel AT
    Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
    Gielen SC; Burger CW; Kühne LC; Hanifi-Moghaddam P; Blok LJ
    J Soc Gynecol Investig; 2005 Oct; 12(7):e55-67. PubMed ID: 16202921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In search of the perfect SERM: beyond tamoxifen and raloxifene.
    McNeil C
    J Natl Cancer Inst; 1998 Jul; 90(13):956-7. PubMed ID: 9665139
    [No Abstract]   [Full Text] [Related]  

  • 16. Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells.
    Eisen SF; Brown HA
    Mol Pharmacol; 2002 Oct; 62(4):911-20. PubMed ID: 12237338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hormone therapy and breast cancer].
    de Cremoux P
    Bull Cancer; 2011 Nov; 98(11):1311-9. PubMed ID: 22020743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modern antioestrogens and the coming revolution in women's health care.
    Evans A; Vollenhoven B; Healy D
    Aust N Z J Obstet Gynaecol; 1999 Aug; 39(3):334-40. PubMed ID: 10554946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of selective estrogen receptor modulators (SERMs).
    Conzen SD
    Cancer J; 2003; 9(1):4-14. PubMed ID: 12602762
    [No Abstract]   [Full Text] [Related]  

  • 20. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
    Peng J; Sengupta S; Jordan VC
    Anticancer Agents Med Chem; 2009 Jun; 9(5):481-99. PubMed ID: 19519291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.